Open AccessUrinary tract infection in the users of depot‐medroxyprogesterone acetate
Author(s) -
Ziaei Saeideh,
Ninavaei Mojgane,
Faghihzadeh Soghrate
Publication year - 2004
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1111/j.0001-6349.2004.00296.x
Subject(s) - medicine , medroxyprogesterone acetate , urinary system , pregnancy , medroxyprogesterone , gynecology , obstetrics , genitourinary system , urology , physiology , estrogen , genetics , biology
Background. The effects of progesterone on muscle tone, peristalsis of the ureter and also urinary vasculature may cause urinary tract infection (UTI) in women who use depot‐medroxyprogesterone acetate (DMPA) for contraception. Methods. In a cohort study, 200 women who chose DMPA for contraception were compared with 200 women who used the withdrawal method for urinary infection and urological symptoms after 3 months of consumption. Results. The rate of urinary infection and urological symptoms in the study group were higher than in the control group ( p = 0.018, p < 0.0001, respectively). The most common microorganism that caused urinary infection was Escherichia coli . Among the 10 cases who suffered UTI in the case group, there were six women who had UTI in the previous pregnancy as well. Conclusion. We do not recommended administering depot‐medroxyprogesterone acetate for contraception in women with a history of urinary tract infection in a previous pregnancy.